An experimental mRNA vaccine significantly reduced the risk of skin cancer recurrence and death in patients when used in combination with the immunotherapy Keytruda, Moderna and Merck announced this month.
Skin cancer is the most commonly diagnosed cancer in the U.S., with melanoma being the most serious type.
Trial: 44 Percent of Patients Reduced Cancer Recurrence or Death
The randomized trial included 157 patients with stage III or IV melanoma who had previously undergone surgery, according to data provided by the drug manufacturers.
George Citroner
Author
George Citroner reports on health and medicine, covering topics that include cancer, infectious diseases, and neurodegenerative conditions. He was awarded the Media Orthopaedic Reporting Excellence (MORE) award in 2020 for a story on osteoporosis risk in men.
